DexCom stock: buy or sell?
November 15th, 2019
DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Should I buy DexCom stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups match with DexCom stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is DexCom stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we gathered 15 ratings published for DXCM stock in the last 30 days. The general sentiment of these ratings is bullish for DXCM stock, with 11 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-3||BMO Capital Markets||n/a||Outperform|
|2019-8-29||Robert W. Baird||n/a||Outperform|
|2019-8-1||Robert W. Baird||n/a||Outperform|
|2019-8-1||JPMorgan Chase & Co.||n/a||Overweight|
|2019-8-1||Bank of America||n/a||Buy|
DexCom stock analysis
DexCom closed yesterday at $208.37 after marking a new all time high ($208.38) and jumped a very good 2.74%.
DexCom shares touched new all time highs again yesterday, setting highs to $208.38. Shares ended at $208.37 and jumped 2.74%. On August, SMA100d and SMA200d crossed up triggering a rise of 23.82%. From a daily perspective, DXCM is in a short term uptrend after plotting its last bottom ($150.41, on Nov/5) higher than the previous bottom, and its last top ($208.20, on Tuesday) also over the previous top. Now trading in between its last bottom and last top DXCM might consolidate in a plain range, waiting to break out over $208.20 or down under $150.41. On November 7th DXCM price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.
DexCom skyrocketed 5.19% this week and set a new all time high at $208.38. Last week DXCM climbed an exceptional 20.59% in just one week. Late October DXCM plunged a scary -6.47% in just one week. This week was the 3rd green week in a row.
If you observe the weekly chart, price finally broke over the resistance at $162.14 and continued climbing. Since SMA20d and SMA40w crossed up by mid August, DXCM price climbed $52.93 per share (34.05%). Since price and SMA40w lines crossed up by mid June, DXCM climbed $82.39 (65.40%).
DexCom stock price history
DexCom IPO was on April 14th, 2005 at $12.08 per share1. Since then, DXCM stock grew a 1,624.90%, with a yearly average of 116.10%. If you had invested right after DXCM's IPO a $1,000 in DexCom stock in 2005, it would worth $16,249.00 today.
1: Adjusted price after possible price splits or reverse-splits.
DexCom stock historical price chart
DXCM stock reached all-time highs yesterday with a price of $208.38.
DexCom stock price target is $170.60How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 14 price predictions for DXCM stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-3||BMO Capital Markets||Raises Target||$180.00||$190.00||5.6%|
|2019-8-29||Robert W. Baird||Raises Target||$186.00||$195.00||4.8%|
|2019-8-1||UBS Group||Raises Target||$140.00||$160.00||14.3%|
|2019-8-1||Robert W. Baird||Raises Target||$180.00||$186.00||3.3%|
|2019-8-1||Raymond James||Raises Target||$150.00||$172.00||14.7%|
|2019-8-1||JPMorgan Chase & Co.||Raises Target||$170.00||$190.00||11.8%|
|2019-8-1||Bank of America||Raises Target||$162.00||$185.00||14.2%|
|2019-5-2||Raymond James||Lowers Target||$160.00||$150.00||-6.3%|
|2019-4-30||UBS Group||Lowers Target||$150.00||$140.00||-6.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareDexCom presented super good results for 2018-Q4 on February. DexCom rocketed Earnings per Share (EPS) by 237.50%, beating experts estimates of $0.16. DexCom posted $0.54.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw an amazing increase of 43.58% to $1,031.60 M dollars. Nonetheless, its profit margin (compared to revenues) slipped to -12.32%, that is $-127.10 million.
|2013||$160 M||-||$-29.80 M-18.6%||-|
|2014||$259 M||62.00%||$-22.40 M-8.6%||-24.83%|
|2015||$402 M||55.09%||$-57.60 M-14.3%||157.14%|
|2016||$573 M||42.61%||$-65.60 M-11.4%||13.89%|
|2017||$719 M||25.33%||$-50.20 M-7.0%||-23.48%|
|2018||$1,032 M||43.58%||$-127.10 M-12.3%||153.19%|
Quarterly financial resultsDexCom reported $338.00 million in revenues for 2018-Q4, a 26.73% improvement compared to previous quarter. Reported quarter income marked $-179.70 million with a profit margin of -53.17%. Profit margin plunged a -70.64% compared to previous quarter when profit margin was 17.47%. When comparing sales to same quarter last year, DexCom sales marked an outstanding gain and skyrocketed a 52.94%. Looking back to recent quarterly results, DexCom posted 3 positive quarters in a row.
|2017-Q2||$171 M||-||$2.90 M1.7%||-|
|2017-Q3||$185 M||8.21%||$-2.00 M-1.1%||-168.97%|
|2017-Q4||$221 M||19.72%||$-9.40 M-4.3%||370.00%|
|2018-Q1||$184 M||-16.56%||$-24.20 M-13.1%||157.45%|
|2018-Q2||$243 M||31.51%||$30.20 M12.5%||-224.79%|
|2018-Q3||$267 M||9.98%||$46.60 M17.5%||54.30%|
|2018-Q4||$338 M||26.73%||$-179.70 M-53.2%||-485.62%|
|2019-Q1||$281 M||-17.01%||$-26.90 M-9.6%||-85.03%|
DexCom ownershipWhen you are planning to invest in a company, it's worth to have a look its ownership structure.
DexCom shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.14% of all shares.
Bearish positions for DXCM stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$19.1 B||$151.7 B||$67.0 B||$51.2 B||$354.9 B|
|Total shares||91.5 M||1,770.0 M||270.0 M||208.6 M||2,630.0 M|
|Float shares||90.3 M||1,760.0 M||269.9 M||207.1 M||2,630.0 M|
|- Institutional holdings (%)||100.2%||76.5%||87.5%||0.0%||69.2%|
|- Insider holdings (%)||1.1%||0.7%||0.3%||3.9%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$202.02 - $208.38|
|Average true range||$9.38|
|50d mov avg||$159.71|
|100d mov avg||$158.17|
|200d mov avg||$144.80|
DexCom performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We picked , Becton, Dickinson and, Edwards Lifesciences, , Medtronic, Quidel, Tandem Diabetes Care and West Pharmaceutical Services as the bechmarking frame for DexCom stock.
|TNDMTandem Diabetes C...||9.38%||-4.26%||91.91%|
DexCom competitorsWe chose a few stocks to conform a list of DexCom competitors to watch if you are interested in investing in DXCM:
- Becton, Dickinson and (BDX)
- Edwards Lifesciences (EW)
- Medtronic (MDT)
- Quidel (QDEL)
- Tandem Diabetes Care (TNDM)
- West Pharmaceutical Services (WST)
Latest DexCom stock news
- InvestorPlaceDexCom Stock Skyrockets on Q2 Earnings BeatAugust 2, 2018